Dimitar Tonev
IQVIA, United Kingdom
Biography
Dimitar Tonev was trained as an Internal Disease Specialist in Sofi a Medical Academy with two
subsequent specializations in Gastroenterology/Hepatology and Pharmaceutical Medicine. He is
trilingual with 11 years of experience in Clinical Practice and 20 years of Clinical development and
medical affairs. During this time, he served as a Medical monitor for a variety of clinical trials in
motility and acid related disorders; HCV-PACIFIC, STEPS in G3, PRINCIPAL; HBV ENTEBE trial
as well as studies in pandemic infl uenza and HIV co-infection. In the last four years he has created
ICPT Medical organization across EU, Canada and Australasia and contributed to pivotal trials in
NASH, PBC, PSC and biliary acid diarrhea. He has been an invited Speaker at National (BASL,
BVHG) and International level (Global NASH Conference). He joined IQVIA as Medical Strategy
Lead for liver diseases and is responsible for building our internal capabilities related to NASH
in Europe. He is also a Chief investigator for the NASH cost-effectiveness study Radical1 in the
UK and has an Operational oversight of more than 20 commercial NASH studies via diagnostic
vendors he is consulting.
Abstract
Abstract : Nonalcoholic fatty liver disease (NAFLD)